Monopar Therapeutics Liabilities And Stockholders Equity Over Time
| MNPR Stock | USD 25.82 2.03 8.53% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Monopar Therapeutics Performance and Monopar Therapeutics Correlation. Monopar |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Monopar Therapeutics. If investors know Monopar will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Monopar Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.98) | Return On Assets (0.53) | Return On Equity (1.02) |
The market value of Monopar Therapeutics is measured differently than its book value, which is the value of Monopar that is recorded on the company's balance sheet. Investors also form their own opinion of Monopar Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Monopar Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Monopar Therapeutics' market value can be influenced by many factors that don't directly affect Monopar Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Monopar Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Monopar Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Monopar Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Liabilities And Stockholders Equity Analysis
Compare Monopar Therapeutics and related stocks such as Anebulo Pharmaceuticals, Acrivon Therapeutics,, and Pmv Pharmaceuticals Liabilities And Stockholders Equity Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ANEB | 3 M | 3 M | 3 M | 3 M | 3 M | 3 M | 3 M | 3 M | 3 M | 3 M | 21.7 M | 15.6 M | 11.7 M | 4.1 M | 3.9 M |
| ACRV | 2.2 M | 2.2 M | 2.2 M | 2.2 M | 2.2 M | 2.2 M | 2.2 M | 2.2 M | 2.2 M | 2.2 M | 2.2 M | 106.6 M | 181.2 M | 138.3 M | 117.8 M |
| MOLN | 110.1 M | 110.1 M | 110.1 M | 110.1 M | 194 M | 219.4 M | 184.1 M | 144.4 M | 155.2 M | 104.9 M | 187.5 M | 172.7 M | 262.3 M | 198.4 M | 193.3 M |
| MLYS | 1.5 M | 1.5 M | 1.5 M | 1.5 M | 1.5 M | 1.5 M | 1.5 M | 1.5 M | 1.5 M | 1.5 M | 1.5 M | 11.1 M | 114.4 M | 251.6 M | 264.2 M |
| CADL | 45.9 M | 45.9 M | 45.9 M | 45.9 M | 45.9 M | 45.9 M | 45.9 M | 45.9 M | 45.9 M | 45.9 M | 38.3 M | 89.2 M | (69.1 M) | 41.2 M | 23.3 M |
| ACXP | 2.5 M | 2.5 M | 2.5 M | 2.5 M | 2.5 M | 2.5 M | 2.5 M | 2.5 M | 2.5 M | 2.5 M | 3.2 M | 13.3 M | 9.4 M | 7.7 M | 7.9 M |
| SCPH | 1.8 M | 1.8 M | 1.8 M | 1.8 M | 1.8 M | 1.8 M | 39.8 M | 122 M | (81.4 M) | (103.5 M) | (134.8 M) | (167.1 M) | (174.8 M) | 94.5 M | 99.2 M |
| DMAC | 216.3 K | 6.3 M | 3.8 M | 2.9 M | 281.6 K | 222.4 K | 1.9 M | 1.8 M | 18.3 M | 9.1 M | 28.1 M | 45.6 M | 34.4 M | 54.2 M | 56.9 M |
| KTTA | 248 K | 248 K | 248 K | 248 K | 248 K | 248 K | 248 K | 248 K | 248 K | 248 K | 248 K | 53.3 M | 45.2 M | 26.1 M | 34.3 M |
| ANTX | 5.7 M | 5.7 M | 5.7 M | 5.7 M | 5.7 M | 5.7 M | 5.7 M | 5.7 M | 5.7 M | 5.7 M | 4.2 M | 65.3 M | 102.6 M | 138.7 M | 69.6 M |
| PHVS | 4.8 M | 4.8 M | 4.8 M | 4.8 M | 4.8 M | 4.8 M | 4.8 M | 4.8 M | 5.4 M | 20.6 M | 101.1 M | 212.1 M | 167.7 M | 398.7 M | 418.6 M |
| PEPG | 4.2 M | 4.2 M | 4.2 M | 4.2 M | 4.2 M | 4.2 M | 4.2 M | 4.2 M | 4.2 M | 4.2 M | 10.6 M | 143.6 M | 217.4 M | 143.1 M | 114.2 M |
| AVTE | 3.5 M | 3.5 M | 3.5 M | 3.5 M | 3.5 M | 3.5 M | 3.5 M | 3.5 M | 3.5 M | 3.5 M | 4.7 M | 175.4 M | 135.3 M | 127.4 M | 98.2 M |
| ADAG | 54.4 M | 54.4 M | 54.4 M | 54.4 M | 54.4 M | 54.4 M | 54.4 M | 54.4 M | 54.4 M | 105.9 M | 84.3 M | 189.5 M | 152.4 M | 115.7 M | 128.7 M |
| RZLT | 5.1 K | 5.1 K | 1.1 M | 7.4 M | 11.3 M | 10.9 M | 10.6 M | 2.5 M | 12.3 M | 11 M | 42.6 M | 152.4 M | 123.7 M | 132.7 M | 139.4 M |
Monopar Therapeutics and related stocks such as Anebulo Pharmaceuticals, Acrivon Therapeutics,, and Pmv Pharmaceuticals Liabilities And Stockholders Equity description
The total of all liabilities and equity in the company, which should equal the company's total assets according to the accounting equation.My Equities
My Current Equities and Potential Positions
| Monopar Therapeutics | MNPR |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | Illinois; U.S.A |
| Exchange | NASDAQ Exchange |
USD 25.82
Additional Tools for Monopar Stock Analysis
When running Monopar Therapeutics' price analysis, check to measure Monopar Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Monopar Therapeutics is operating at the current time. Most of Monopar Therapeutics' value examination focuses on studying past and present price action to predict the probability of Monopar Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Monopar Therapeutics' price. Additionally, you may evaluate how the addition of Monopar Therapeutics to your portfolios can decrease your overall portfolio volatility.